J INTS BIO Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
28
- Latest Deal Type
-
Series C
- (In Progress)
- Latest Deal Amount
-
$12.2M
- Investors
-
6
J INTS BIO General Information
Description
Operator of a bioscience company intended to specialize in the development of anticancer drugs and orphan drugs. The company offers AI-driven computing infrastructure, comprehensive multi-omics data analysis, and global regulatory-ready pipelines, enabling oncologists, biopharmaceutical partners, and healthcare providers to bring therapies to patients with unmet treatment needs for breast cancer, ovarian cancer, and pancreatic cancer.
Contact Information
Website
www.jintsbio.comCorporate Office
- 49, Achasan-ro 17-gil
- 311-313, Saenggak Factory Desianplex, Seongdong-gu
- Seoul
- South Korea
Corporate Office
- 49, Achasan-ro 17-gil
- 311-313, Saenggak Factory Desianplex, Seongdong-gu
- Seoul
- South Korea
J INTS BIO Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC (Series C) | 26-Mar-2026 | $12.2M | In Progress | Clinical Trials - Phase 1 | ||
| 2. Early Stage VC (Series B) | 30-Sep-2023 | Completed | Clinical Trials - Phase 1 | |||
| 1. Seed Round | 01-Jan-2022 | $3.37M | $3.37M | Completed | Clinical Trials - Phase 1 |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
J INTS BIO Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
J INTS BIO Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
J INTS BIO Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Moneyball Ventures | Venture Capital | Minority | ||
| Anda Asia Ventures | Venture Capital | Minority | ||
| SYP | Accelerator/Incubator | Minority | ||
| Yuhan | Corporation | Minority | ||
| Angel (individual) | Minority |
J INTS BIO FAQs
-
When was J INTS BIO founded?
J INTS BIO was founded in 2020.
-
Where is J INTS BIO headquartered?
J INTS BIO is headquartered in Seoul, South Korea.
-
What is the size of J INTS BIO?
J INTS BIO has 28 total employees.
-
What industry is J INTS BIO in?
J INTS BIO’s primary industry is Drug Discovery.
-
Is J INTS BIO a private or public company?
J INTS BIO is a Private company.
-
What is the current valuation of J INTS BIO?
The current valuation of J INTS BIO is .
-
What is J INTS BIO’s current revenue?
The current revenue for J INTS BIO is .
-
How much funding has J INTS BIO raised over time?
J INTS BIO has raised $3.37M.
-
Who are J INTS BIO’s investors?
Moneyball Ventures, Anda Asia Ventures, SYP, Yuhan, and are 5 of 6 investors who have invested in J INTS BIO.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
